MusclePharm (MSLPQ) 10-Q9 Nov 152015 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	MSLP
Entity Registrant Name	MusclePharm Corp
Entity Central Index Key	1,415,684
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,731,929

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 3,457	$ 1,020
Accounts receivable, net of allowance for doubtful accounts of $297 and $159 as of September 30, 2015 and December 31, 2014	15,586	16,644
Inventory	19,320	21,069
Prepaid giveaways	501	1,228
Prepaid stock compensation, current portion	2,344	4,476
Prepaid sponsorship and endorsement fees	541	238
Prepaid expenses and other current assets	3,420	1,742
Total current assets	45,169	46,417
Property and equipment, net	7,008	7,805
Long-term investments	977
Intangible assets, net	8,904	7,074
Prepaid stock compensation, noncurrent portion		4,952
Other assets	185	108
TOTAL ASSETS	62,243	66,356
Current liabilities:
Accounts payable	40,442	27,761
Accrued liabilities	10,986	7,023
Accrued restructuring charges	10,097
Line of credit	2,635	8,000
Term loan	3,269
Other debt obligations	21	46
Total current liabilities	67,450	42,830
Other long-term liabilities	342	146
TOTAL LIABILITIES	$ 67,792	$ 42,976
Commitments and contingencies (Note 9)
Stockholders' (deficit) equity:
Common stock, par value of $0.001 per share; 100,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 14,607,550 and 13,996,007 shares issued as of September 30, 2015 and December 31, 2014; 13,731,929 and 13,120,386 shares outstanding as of September 30, 2015 and December 31, 2014	$ 14	$ 14
Additional paid-in capital	142,458	129,130
Treasury stock, at cost; 875,621 shares as of September 30, 2015 and December 31, 2014	(10,039)	(10,039)
Accumulated other comprehensive loss	(171)	(66)
Accumulated deficit	(137,811)	(95,659)
TOTAL STOCKHOLDERS' (DEFICIT) EQUITY	(5,549)	23,380
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	$ 62,243	$ 66,356

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 297	$ 159
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	14,607,550	13,996,007
Common Stock, shares outstanding	13,731,929	13,120,386
Treasury Stock, shares	875,621	875,621

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue, net	$ 33,982	$ 47,768	$ 125,780	$ 144,718
Cost of revenue (including restructuring charges of $1,262 related to write-down of inventory for the three months and nine months ended September 30, 2015)	23,512	32,812	83,428	96,242
Gross profit	10,470	14,956	42,352	48,476
Operating expenses:
Advertising and promotion	7,093	7,749	22,603	19,997
Salaries and benefits	5,681	6,041	20,505	17,185
Selling, general and administrative	4,647	3,652	14,730	7,881
Research and development	1,437	735	3,323	2,996
Professional fees	1,980	1,316	5,499	3,393
Restructuring and other charges	16,650		16,650
Total operating expenses	37,488	19,493	83,310	51,452
Loss from operations	(27,018)	(4,537)	(40,958)	(2,976)
Other (expense) income, net	(559)	5,234	(1,090)	5,551
(Loss) income before provision for income taxes	(27,577)	697	(42,048)	2,575
Provision for income taxes	71	94	104	171
Net (loss) income	$ (27,648)	$ 603	$ (42,152)	$ 2,404
Net (loss) income per share, basic	$ (2.01)	$ 0.05	$ (3.12)	$ 0.23
Net (loss) income per share, diluted	$ (2.01)	$ 0.05	$ (3.12)	$ 0.20
Weighted-average shares used in computing net (loss) income per share, basic	13,723,213	11,032,996	13,504,455	10,652,781
Weighted-average shares used in computing net (loss) income per share, diluted	13,723,213	12,612,896	13,504,455	12,112,017

Consolidated Statements of Ope5

Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2015	Sep. 30, 2015	Sep. 30, 2015
Income Statement [Abstract]
Restructuring charges related to write-down of inventory	$ 1,300	$ 1,262	$ 1,262

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (27,648)	$ 603	$ (42,152)	$ 2,404
Other comprehensive income (loss):
Change in foreign currency translation adjustment	72	(37)	(105)	(18)
Comprehensive (loss) income	$ (27,576)	$ 566	$ (42,257)	$ 2,386

Consolidated Statement of Stock

Consolidated Statement of Stockholders' (Deficit) Equity (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ 23,380	$ 14	$ 129,130	$ (10,039)	$ (66)	$ (95,659)
Balance (in shares) at Dec. 31, 2014	13,120,386	13,120,386
Issuance of common stock warrants to third parties for services	$ 62		62
Stock-based compensation related to issuance of restricted stock awards to employees, executives and directors, net of cancellations	$ 10,029		10,029
Stock-based compensation related to issuance of restricted stock awards to employees, executives and directors (in shares)	186,354	186,354
Stock issued in conjunction with product line expansion	$ 1,198		1,198
Stock issued in conjunction with product line expansion (in shares)	150,000	150,000
Stock issued in conjunction with MusclePharm apparel rights acquisition	$ 1,394		1,394
Stock issued in conjunction with MusclePharm apparel rights acquisition (in shares)		170,000
Stock issued in conjunction with attempted financing agreement	$ 325		325
Stock issued in conjunction with attempted financing agreement (in shares)	50,000	50,000
Stock issued in conjunction with non-employee consulting/endorsement agreement	$ 320		320
Stock issued in conjunction with non-employee consulting/endorsement agreement (in shares)	55,189	55,189
Change in foreign currency translation adjustment	$ (105)				(105)
Net loss	(42,152)					(42,152)
Balance at Sep. 30, 2015	$ (5,549)	$ 14	$ 142,458	$ (10,039)	$ (171)	$ (137,811)
Balance (in shares) at Sep. 30, 2015	13,731,929	13,731,929

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (42,152,000)	$ 2,404,000
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation of property and equipment	1,330,000	950,000
Amortization of intangible assets	776,000	422,000
Provision for doubtful accounts	168,000	164,000
Non-cash restructuring and other charges	8,430,000
Inventory write down related to corporate restructuring	1,262,000
Amortization of prepaid stock compensation	3,198,000	2,582,000
Amortization of prepaid sponsorship and endorsement fees	5,363,000	5,016,000
Accretion of discount on marketable securities		(15,000)
Amortization of debt issuance costs	29,000	1,000
Stock-based compensation	8,690,000	6,872,000
Issuance of common stock warrants to third parties for services	62,000	69,000
Bargain purchase gain and contingent asset gain on BioZone acquisition		(5,265,000)
Gain on settlement of accounts payable		(31,000)
Loss on disposal of property and equipment	32,000
Change in fair value of derivative liabilities		(374,000)
Realized gain on marketable securities		(96,000)
Changes in operating assets and liabilities:
Accounts receivable	890,000	(9,148,000)
Inventory	487,000	(7,424,000)
Prepaid giveaways	727,000	(257,000)
Prepaid sponsorship and endorsement fees	(6,492,000)	(4,377,000)
Prepaid expenses and other current assets	(1,822,000)	(720,000)
Other assets	(77,000)	(127,000)
Accounts payable	(14,928,000)	1,870,000
Accrued liabilities	3,903,000	1,604,000
Accrued restructuring charges	(7,977,000)
Net cash provided by (used in) operating activities	7,709,000	(5,880,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(1,251,000)	(3,535,000)
Sale proceeds from settlement of marketable securities		490,000
Change in restricted cash balance		2,500,000
Proceeds from disposal of property and equipment	447,000	2,000
Purchase of MusclePharm apparel rights	(850,000)
Purchase of trademarks	(262,000)
Investment in contract manufacturer	(977,000)
Net cash used in investing activities	(2,893,000)	(543,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from line of credit	9,142,000	7,918,000
Payments on line of credit	(14,507,000)	(2,500,000)
Repayments of term loan	(731,000)	(17,000)
Repurchase of common stock		(1,363,000)
Proceeds from issuance of term loan	4,000,000
Issuance costs of term loan	(40,000)
Repayments of other debt obligations	(25,000)
Repayment of capital lease obligations	(113,000)	(59,000)
Net cash (used in) provided by financing activities	(2,274,000)	3,979,000
Effect of exchange rate changes on cash	(105,000)	(18,000)
Net increase (decrease) in cash and cash equivalents	2,437,000	(2,462,000)
Cash and cash equivalents, beginning of period	1,020,000	5,412,000
Cash and cash equivalents, end of period	3,457,000	2,950,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for income taxes	57,000	240,000
Cash paid for interest	384,000	79,000
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION
Stock issued in conjunction with acquisition	1,394,000
Stock issued for future services - third parties		5,403,000
Reclassification of derivative liability to additional paid-in capital and warrant settlements		773,000
Capital leases	423,000	89,000
Purchase of property and equipment included in accounts payable and accrued liabilities	148,000	169,000
Trademark registration included in accounts payable	100,000
Muscle Pharm Apparel [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION
Stock issued in conjunction with acquisition	$ 1,394,000
Biozone Asset Acquisition [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION
Stock issued in conjunction with acquisition		$ 8,833,000

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
Description of Business and Basis of Presentation	Sep. 30, 2015
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Note 1: Description of Business and Basis of Presentation Description of Business MusclePharm Corporation, or the Company, was incorporated in Nevada in 2006. The Company is a scientifically driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company is headquartered in Denver, Colorado and has the following wholly-owned operating subsidiaries: MusclePharm Canada Enterprises Corp (“MusclePharm Canada”), BioZone Laboratories, Inc. (“BioZone Labs”) and MusclePharm Ireland Limited (“MusclePharm Ireland”). On August 24, 2015, the board of directors approved a restructuring plan for the Company. The approved restructuring plan was designed to reduce costs and to better align the Company’s resources for profitable growth. Specifically, during the quarter ended September 30, 2015, the restructuring plan resulted in: 1) a reduction in the Company’s workforce; 2) the Company abandoning certain leased facilities; and 3) the Company renegotiating or terminating a number of contracts with endorsers in a strategic shift away from such arrangements and towards more grass-roots marketing and advertising efforts. Management is continuing to execute on the approved restructuring plan, and as such, additional restructuring charges may be necessary in the fourth quarter of 2015. See Note 8 to the consolidated financial statements for further detail. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Reclassifications Certain amounts in the consolidated statement of cash flows for the nine months ended September 30, 2014 were revised to conform to the consolidated statement of cash flows for the year ended December 31, 2014 and the current period presentation. These adjustments resulted in an increase in net cash used in operating activities of $335,000, a decrease in net cash used in investing activities of $2.9 million, and a decrease in net cash provided by financing activities of $2.6 million.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2: Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements have been prepared in accordance with GAAP. In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of September 30, 2015, our results of operations for the three and nine months ended September 30, 2015 and 2014, and our cash flows for the nine months ended September 30, 2015 and 2014. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 16, 2015. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory, the assessment of useful lives and recoverability of long-lived assets, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates. Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which provides guidance on simplifying the presentation of debt issuance costs, requiring that debt issuance costs related to a recognized debt liability be presented in the consolidated balance sheets as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No, 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”), which further clarifies ASU 2015-03 as it relates to presentation and subsequent measurement of debt issuance costs related to line-of-credit arrangements. ASU 2015-15 allows an entity deferring and presenting debt issuance costs related to line-of-credit arrangements as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. Both ASU 2015-03 and ASU 2015-15 require retrospective adoption and will be effective for financial statement periods beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted. The Company has not early adopted ASU 2015-03 or ASU 2015-15 and the adoption of these standards is not expected to have a material effect on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15. In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the consolidated financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s consolidated financial statements or disclosures. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2018 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is permitted beginning January 1, 2017. The Company has not yet selected a transition method nor determined the effect of ASU 2014-09 on its ongoing financial reporting.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3: Fair Value of Financial Instruments Management believes the fair value of the line-of-credit and term loan approximates carrying value because the debt carries market rates of interest. The Company’s remaining financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, and accrued restructuring charges, all of which are short-term in nature with fair values approximating carrying value.

Capstone Nutrition Agreements

Capstone Nutrition Agreements	9 Months Ended
Capstone Nutrition Agreements	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capstone Nutrition Agreements	Note 4: Capstone Nutrition Agreements The Company entered into a series of agreements with Capstone Nutrition (“F.H.G. Corporation”) effective March 2, 2015, including an amendment (the “Amendment”) to a Manufacturing Agreement dated November 27, 2013 (the “Manufacturing Agreement”). Pursuant to the Amendment, Capstone shall be the Company’s nonexclusive manufacturer of dietary supplements and food products sold or intended to be sold by the Company. The Amendment includes various agreements including amended pricing terms. The initial term ends January 1, 2022, and may be extended for three successive twenty-four month terms and includes renewal options. Contribution toward Capstone Facility Build-Out The Company and Capstone entered into a Class B Common Stock Warrant Purchase Agreement (“Warrant Agreement”) whereby the Company may purchase approximately 19.9% of Capstone’s parent company, INI Parent, Inc. (“INI”), on a fully-diluted basis as of March 2, 2015. Pursuant to the Warrant Agreement, INI issued to the Company a warrant (the “Warrant”) to purchase shares of INI’s Class B common stock, par value $0.001 per share at an exercise price of $0.01 per share (the “Warrant Shares”). The warrant may be exercised if the Company is in compliance with the terms and conditions of the Amendment. The Company determined the value of the warrants and recorded an asset of $977,000, which is included in the caption long-term investments on the consolidated balance sheet as of September 30, 2015. The Company also recorded $1.5 million of prepaid expenses and other assets on the consolidated balance sheet as of September 30, 2015 and will be amortized over the remaining life of the Manufacturing Agreement of 6.5 years. The Company and INI also entered into an option agreement (the “Option Agreement”). Subject to additional provisions and conditions set forth in the Option Agreement, at any time on or prior to June 30, 2016, the Company shall have the right to purchase for cash all of the remaining outstanding shares of INI’s common stock not already owned by the Company after giving effect to the exercise of the Warrant, based on an aggregate enterprise value, equal to $200 million. The fair value of the option was deemed de minimus as of the transaction date.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
Balance Sheet Components	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Note 5: Balance Sheet Components Inventory Inventory consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 1,603 $ 1,169 Work-in-process 151 101 Finished goods 17,566 19,799 Inventory $ 19,320 $ 21,069 The Company writes down inventory for obsolete and slow moving inventory based on the age of the product as determined by the expiration date. Products within one year of their expiration dates are considered for write-off purposes. Historically, the Company has had minimal returns with established customers, and any damaged packaging is sent back to the manufacturer for replacement. Other than write-down of inventory during restructuring activities, the Company incurred insignificant inventory write-offs during the three and nine months ended September 30, 2015 and 2014. As disclosed further in Note 8, the Company executed a restructuring plan in August 2015 and recorded a write-down of inventory related to discontinued products of $1.3 million. Inventory write downs are included as a component of cost of revenue in the accompanying consolidated statements of operations. Inventory write-downs, once established, are not reversed as they establish a new cost basis for the inventory. Property and Equipment Property and equipment consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Furniture and fixtures $ 3,091 $ 4,041 Leasehold improvements 3,053 2,298 Manufacturing and lab equipment 1,577 1,388 Vehicles 1,081 470 Displays 485 488 Website 463 241 Office equipment and computers 520 — Construction in process 281 1,511 Property and equipment, gross 10,551 10,437 Less: accumulated depreciation and amortization (3,543 ) (2,632 ) Property and equipment, net $ 7,008 $ 7,805 Depreciation and amortization expense related to property and equipment was $492,000 and $303,000 for the three months ended September 30, 2015 and 2014, respectively, and $1.3 million and $950,000 for the nine months ended September 30, 2015 and 2014, respectively. These expenses are included in the selling, general and administrative expenses in the consolidated statements of operations. As disclosed further in Note 8, the Company executed a restructuring plan in August 2015 and wrote-off certain long-lived assets, primarily leasehold improvements, related to the abandonment of certain leased facilities. The write-off of long-lived assets of $380,000 is included as a component of restructuring and other charges in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2015. Intangible Assets Intangible assets consist of the following (in thousands) and include the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel disclosed further in Note 11: September 30, 2015 Gross Value Accumulated Amortization Net Carrying Value Weighted- Average Useful Lives (Years) Amortized Intangible Assets Customer relationships $ 3,130 $ (365 ) $ 2,765 15.0 Non-compete agreements 69 (60 ) 9 2.0 Patents 2,211 (505 ) 1,706 7.9 Trademarks 880 (98 ) 782 6.7 Brand 4,020 (413 ) 3,607 10.5 Domain name 68 (33 ) 35 5.0 Total intangible assets $ 10,378 $ (1,474 ) $ 8,904 December 31, 2014 Gross Value Accumulated Amortization Net Carrying Value Weighted- Average Useful Lives (Years) Amortized Intangible Assets Customer relationships $ 3,130 $ (209 ) $ 2,921 15.0 Non-compete agreements 69 (35 ) 34 2.0 Patents 2,211 (293 ) 1,918 7.9 Trademarks 518 (20 ) 498 4.5 Brand 1,776 (118 ) 1,658 15.0 Domain name 68 (23 ) 45 5.0 Total intangible assets $ 7,772 $ (698 ) $ 7,074 Intangible assets amortization expense was $278,000 for the three months ended September 30, 2015. During the three months ended September 30, 2014, the Company completed the final valuation of assets acquired from BioZone including the estimated useful lives. As a result, the Company realized a credit of $156,000 in intangible assets amortization based upon the final estimated useful life and true up of amortization expense from the acquisition date to September 30, 2014. Intangible assets amortization expense was $776,000 and $422,000 for the nine months ended September 30, 2015 and 2014, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations. As of September 30, 2015, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2015 $ 280 2016 1,087 2017 1,067 2018 1,056 2019 1,052 2020 1,023 Thereafter 3,339 Total amortization expense $ 8,904

Other (Expense) Income, net

Other (Expense) Income, net	9 Months Ended
Other (Expense) Income, net	Sep. 30, 2015
Other Income and Expenses [Abstract]
Other (Expense) Income, net	Note 6: Other (Expense) Income, net During the three and nine months ended September 30, 2015 and 2014, other (expense) income, net consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Other (expense) income, net: Interest income $ — $ — $ — $ 223 Interest expense (99 ) (29 ) (357 ) (85 ) Change in fair value of derivative liabilities — — — 374 Gain on settlement of accounts payable — — — 31 Loss on marketable securities — — — (386 ) Bargain purchase gain and contingent asset gain on BioZone asset acquisition — 5,265 — 5,265 Foreign currency loss (456 ) (2 ) (717 ) (36 ) Other (4 ) — (16 ) 165 Total other (expense) income, net $ (559 ) $ 5,234 $ (1,090 ) $ 5,551

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	Note 7: Debt The Company’s debt obligations consist of the following (in thousands): September 30, December 31, Line of credit $ 2,635 $ 8,000 Term loan 3,269 — Total debt obligations $ 5,904 $ 8,000 In September 2014, the Company entered into a line of credit facility with a banking institution for up to $8.0 million of borrowings. The line of credit renews annually and matures in September 2017 and accrues interest at the prime rate plus 2%, currently 5.25%. The line of credit is secured by the Company’s inventory, accounts receivable, intangible assets and equipment. As of September 30, 2015, the outstanding borrowings under the line of credit were $2.6 million. The Company was not in compliance with certain financial covenants under the line of credit as of September 30, 2015 a result of which limits further borrowings, and received various waivers from the lender during the period. In February 2015, the Company entered into a term loan agreement with the same banking institution for a principal amount of $4.0 million. The term loan carries a fixed interest rate of 5.25% per annum, is repayable in 36 equal monthly installments of principal and interest, and matures in February 2018. Outstanding borrowings are subject to prepayment penalties of 1.0% of the prepayment amount. The Company also paid debt issuance costs of $40,000 which were recorded in prepaid expenses and other current assets in the consolidated balance sheets. As of September 30, 2015, the outstanding borrowings under the term loan were $3.3 million. The term loan contains various events which could require repayment, including in connection with the line of credit. Borrowings on the term loan are secured by the Company’s assets and 860,900 shares of its common stock which are reported as treasury shares. The Company is also required to comply with certain negative covenants under the term loan, including restrictions on indebtedness, investments, asset dispositions, mergers or consolidations and other corporate activities. The Company was not in compliance with certain financial covenants under the term loan as of September 30, 2015 and received various waivers from the lender during the period. On October 9, 2015, the Company entered into loan modification agreements with the banking institution under its line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, the Company’s chairman of the board of directors and a family member provided their individual guaranty for the remaining balance of the loans ($6.2 million). In consideration for executing his guaranty, the Company issued chairman of the board of directors 28,571 shares of its common stock with a grant date fair value of $80,000 (based upon the closing price of common stock on the date of issuance).

Restructuring

Restructuring	9 Months Ended
Restructuring	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring	Note 8: Restructuring As part of an effort to better focus and align the Company’s resources toward profitable growth, on August 24, 2015, the board of directors authorized the Company to undertake steps to commence a restructuring of the business and operations. The Company closed certain facilities, reduced headcount, discontinued products, and renegotiated certain contracts resulting in a restructuring and other charges of $17.9 million, of which $1.3 million related to inventory was included in cost of revenue and $16.6 million was included in operating expenses in the accompanying consolidated statements of operations. For the three and nine months ended September 30, 2015, restructuring charges of $8.2 million, to be paid in cash, were comprised primarily of: (i) $1.2 million related to severance and termination benefit costs related to the terminated employees; (ii) $6.6 million related to cancellation of certain contracts and sponsorship agreements, which are payable through December 2016; and (iii) $454,000 for costs associated with permanently vacating certain leased facilities. The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of September 30, 2015 (in thousands): Employee Contract Abandoned Total Balance as of December 31, 2014 $ — $ — $ — $ — Expensed 1,166 6,600 454 8,220 Cash payments (235 ) — (8 ) (243 ) Reclassification from accounts payable related to cancellation of certain contracts and sponsorship agreements — 2,120 — 2,120 Balance as of September 30, 2015 $ 931 $ 8,720 $ 446 $ 10,097 As a result of the reduction in force, 325,421 shares of restricted common stock vested in accordance with the original stock grant terms and condition and resulted in the recognition of employee stock based compensation of $1.7 million. During the three months ended September 30, 2015, in association with the restructuring, the Company recorded the following charges totaling $8.4 million (in thousands): Operating Expenses Employee Stock based compensation $ 1,692 Write-down of prepaid stock compensation related to terminated endorsement agreements, discontinued products and abandoned other arrangements including related prepaid assets 6,358 Write-off of long-lived assets related to the abandonment of certain lease facilities 380 Total other charges $ 8,430 The Company expects to complete further restructuring activities during the fourth quarter of 2015. The total future payments under the restructuring plan as of September 30, 2015 are as follows (in thousands): Remainder Year ending December 31, Outstanding Payments 2016 2017 2018 2019 2020 Total Contract termination costs $ 1,608 $ 7,112 $ — $ — $ — $ — $ 8,720 Employee severance costs 931 — — — — — 931 Abandoned leased facilities 47 134 98 77 79 11 446 Total future payments $ 2,586 $ 7,246 $ 98 $ 77 $ 79 $ 11 $ 10,097

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9: Commitments and Contingencies Operating Leases and Capital Leases The Company leases office and warehouse facilities under operating leases which expire at various dates through 2029. For lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense was $422,000 and $356,000 for the three months ended September 30, 2015 and 2014, respectively, and $1.2 million and $989,000 for the nine months ended September 30, 2015 and 2014, respectively. In December 2014, the Company entered into a capital lease agreement providing for approximately $1.8 million in credit to lease up to 50 vehicles as part of a fleet lease program. As of September 30, 2015, the Company acquired 19 vehicles under the capital lease, which are included in the caption property and equipment, net in the accompanying consolidated balance sheets. The Company also leases manufacturing and warehouse equipment under capital leases, which expire at various dates through May 2019. As of September 30, 2015 and December 31, 2014, the Company had outstanding balances on capital leases of $519,000 and $265,000, respectively, which were included as a component of accrued liabilities and other long-term liabilities in the consolidated balance sheets. As of September 30, 2015, the Company’s future minimum lease payments are as follows (in thousands): Year Ending December 31, The remainder of 2015 $ 51 2016 198 2017 152 2018 117 2019 46 Total minimum lease payments 564 Less amounts representing interest (45 ) Present value of minimum lease payments $ 519 Contingencies In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible losses can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of September 30, 2015 and December 31, 2014, the Company was not involved in any material legal proceedings, except for the SEC investigation discussed below and routine litigation and claims (primarily trademark disputes) experienced in the ordinary course of its business and as otherwise described in this Quarterly Report under Item II, Legal Proceedings. SEC Settlement In September 2015, the Company’s proposal regarding final settlement of an SEC ongoing investigation was accepted and all aspects of the investigation related to the Company were terminated. The Company, without admitting or denying the SEC claims, agreed to payment of $700,000 which was previously accrued for and $400,000 had already been paid into escrow. The Company also agreed to appointment of an independent consultant mutually acceptable to the Company for a 12-month period to monitor the Company’s reporting practices in several regards and appointed Chord Advisors, LLC, a New York consulting firm. Insurance Carrier Lawsuit On February 12, 2015, the Company filed a complaint in the District Court, City and County of Denver, Colorado against Liberty Insurance Underwriters, Inc. (“Liberty”) claiming wrongful and unreasonable denial of coverage for the cost and expenses that the Company has incurred and continued to incur in connection with SEC investigation and related matters under the Company’s Directors and Officers Insurance policies. Product Liability Additionally, as a manufacturer of nutritional supplements and other consumer products for ingestion, the Company is subject to various claims in the ordinary course of its business related to labeling (including trademarks), content, packaging, and regulatory requirements. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $20.0 million, however the nature of such claims may not be covered by such insurance. The Company does not maintain any insurance related to recalls or “advertising injury” type of claims. As of September 30, 2015 and December 31, 2014, the Company had not recorded an accrual for product liability or related claims although claims of this nature are routinely asserted against the Company. There can be no assurance that insurance coverage will be available for such claims or similar claims experienced in the ordinary course of the Company’s business. Sponsorship and Endorsement Contract Liabilities The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2022. The total future contractual payments as of September 30, 2015 are as follows (in thousands), although the Company is seeking to terminate or amend certain significant agreements for endorsement or sponsorship, which adjusted terms are not reflected in the below as of September 30, 2015: Remainder Year ending December 31, Future Contractual Payments 2016 2017 2018 2019 2020 Thereafter Total Endorsement $ 850 $ 2,560 $ 2,512 $ 2,500 $ 4,167 $ 5,000 $ 6,667 $ 24,256 Sponsorships 1,211 4,825 3,105 2,729 985 — — 12,855 Total future payments $ 2,061 $ 7,385 $ 5,617 $ 5,229 $ 5,152 $ 5,000 $ 6,667 $ 37,111

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity	9 Months Ended
Stockholders' (Deficit) Equity	Sep. 30, 2015
Equity [Abstract]
Stockholders' (Deficit) Equity	Note 10: Stockholders’ (Deficit) Equity Common Stock For the nine months ended September 30, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors, net of cancellations 186,354 $ 10,029 $ 3.48–8.60 Stock issued in conjunction with product line expansion 150,000 1,198 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 8.20 Stock issued in conjunction with attempted financing agreement 50,000 325 6.49 Stock issued in conjunction with consulting/endorsement agreement 55,189 320 5.30–5.85 Total 611,543 $ 13,266 $ 3.48–8.60 For the nine months ended September 30, 2014, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 66,878 $ 316 $ 3.48–8.70 BioZone acquisition (1) 1,200,000 8,833 8.20 Conversion of series D preferred stock to common stock 263,000 773 2.94 Deferred stock compensation on restricted stock awards issued for endorsement agreements 476,853 5,403 11.19–13.41 Total 2,006,731 $ 15,325 $ 2.94–13.41 (1) Subsequently reduced by 350,000 shares returned to treasury with a value of $4.6 million. The fair value of all stock issuances above is based upon either the quoted closing trading price on the date of issuance or the value of derivative instruments at the date of conversion. Treasury Stock For the nine months ended September 30, 2015, the Company did not repurchase any shares of its common stock and held 875,621 shares in treasury as of September 30, 2015 (of which 860,900 shares are subject to a pledge with a lender). For the nine months ended September 30, 2014, the Company’s treasury stock transactions are as follows: Transaction Type Number of Shares Weighted-Average Purchase of common stock in open market under the 2013 Stock Repurchase Plan 100,000 $ 13.63 Settlement of common stock held in escrow during BioZone acquisition (1) 350,000 13.20 Total 450,000 $ 13.30 (1) Returned to treasury.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 11: Stock-Based Compensation The Company’s stock-based compensation for the nine months ended September 30, 2015 consists primarily of restricted stock awards. The activity of restricted stock awards granted to employees, executives, and board members was as follows: Number of Shares Weighted- Date Fair Value Unvested balance – December 31, 2014 2,631,987 $ 11.67 Granted 243,217 4.46 Vested (894,830 ) 10.37 Cancelled (100,000 ) 4.29 Unvested balance – September 30, 2015 1,880,374 $ 11.83 The total fair value of restricted stock awards granted to employees and board members was $184,000 for the three months ended September 30, 2015. No restricted stock awards were granted to employees and board members for the three months ended September 30, 2014. The total fair value of restricted stock awards granted to employees and board members was $1.1 million and $1.5 million for the nine months ended September 30, 2015 and 2014, respectively. As of September 30, 2015 and December 31, 2014, the total unrecognized expense for unvested restricted stock awards, net of expected forfeitures, was $11.3 million and $20.7 million, respectively, which are expected to be amortized over a weighted-average period of 3.0 and 2.6 years, respectively. Restricted Stock Awards Related to Energy Drink Agreement In January 2015, the Company entered into an energy drink agreement with Langer Juice and Creative Flavor Concepts to expand into a new product line. In connection with the agreement, the Company issued a total of 150,000 shares of its restricted common stock with trade restrictions for a period of three years. The restricted stock awards issued had a grant date fair value of approximately $1.2 million, which were initially included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of ten years. In connection with the restructuring event disclosed further in Note 8, the Company discontinued this product and wrote-off the unamortized prepaid stock compensation of $1.1 million in August 2015. Agreements with Worldwide Apparel, LLC – Muscle Pharm Apparel Rights In February 2015, the Company entered into an agreement with Worldwide Apparel, LLC (“Worldwide”) to terminate Worldwide’s right to use MusclePharm’s brand images in apparel effective March 28, 2015. The brand rights were originally licensed in May 2011, and amended in March 2014 prior to the termination. The consideration related to the acquisition of the MusclePharm Apparel from Worldwide consists of cash consideration of $850,000 and 170,000 shares of MusclePharm common stock with an aggregated fair value of $1.4 million. The total cost of the MusclePharm apparel acquisition of $2.2 million is included in the caption brand within intangible assets, net, in the accompanying consolidated balance sheet, and is subject to amortization over a period of seven years. Restricted Stock Awards Issued Related to Attempted Financing Agreement In May 2015, the Company negotiated the termination of an attempted financing agreement with a lending institution and issued 50,000 shares of its common stock. The fair value of the common stock was $325,000 based upon the closing price of common stock on the date of issuance, and was recorded in selling, general and administrative expense in the accompanying consolidated statement of operations. Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement In May 2015, the Company entered into consulting and endorsement agreements with William Phillips. In connection with the endorsement agreements, the Company agreed to issue a total of 50,000 shares of its restricted common stock. The restricted common stock issued had a grant date fair value of $292,000, which was included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of three years. In connection with the restructuring disclosed in Note 8, the Company terminated the consulting and endorsement agreements with William Phillips and wrote-off the unamortized prepaid stock compensation of $268,000. In connection with the consulting agreement, the Company also agreed to issue restricted shares worth $25,000 (based upon the weighted average stock price during the 15-day-period prior to issuance) within 10 days after each subsequent three-month period term. In July 2015, the Company issued 5,189 shares of its common stock to William Phillips. The fair value of the common stock was $28,000 based upon the closing price of common stock on the date of issuance, and was recorded in advertising and promotion expense in the accompanying consolidated statement of operations. No additional common stock will be issued to William Phillips under this agreement.

Net (Loss) Income per Share

Net (Loss) Income per Share	9 Months Ended
Net (Loss) Income per Share	Sep. 30, 2015
Earnings Per Share [Abstract]
Net (Loss) Income per Share	Note 12: Net (Loss) Income per Share The following table sets forth the computation of the Company’s basic and diluted net (loss) income per share for the periods presented (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net (loss) income $ (27,648 ) $ 603 $ (42,152 ) $ 2,404 Weighted-average common shares used in computing net (loss) income per share, basic 13,723,213 11,032,996 13,504,455 10,652,781 Effect of dilutive securities — 1,579,900 — 1,459,236 Weighted-average common shares used in computing net (loss) income per share, diluted 13,723,213 12,612,896 13,504,455 12,112,017 Net (loss) income per share, basic $ (2.01 ) $ 0.05 $ (3.12 ) $ 0.23 Net (loss) income per share, diluted $ (2.01 ) $ 0.05 $ (3.12 ) $ 0.20 The following securities were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive: As of September 30, 2015 2014 Stock options (exercise price - $425/share) — 472 Warrants (exercise price - $4 - $1,275/share) — 100,089 Unvested restricted stock 1,880,374 1,495,117 Total common stock equivalents 1,880,374 1,595,678

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 13: Income Taxes The Company recorded an income tax provision of $71,000 and $94,000 for the three months ended September 30, 2015 and 2014, respectively, and $104,000 and $171,000 for the nine months ended September 30, 2015 and 2014, respectively, related to foreign income taxes and state minimum taxes. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has established a full valuation allowance as of September 30, 2015 and December 31, 2014 as it is more likely than not that a tax benefit will not be realized.

Geographical Information

Geographical Information	9 Months Ended
Geographical Information	Sep. 30, 2015
Segment Reporting [Abstract]
Geographical Information	Note 14: Geographical Information Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Revenue, net: United States $ 23,676 $ 28,677 $ 91,534 $ 88,718 International 10,306 19,091 34,246 56,000 Total revenue, net $ 33,982 $ 47,768 $ 125,780 $ 144,718

Related-Party Transactions

Related-Party Transactions	9 Months Ended
Related-Party Transactions	Sep. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Note 15: Related-Party Transactions On October 9, 2015, the Company entered into loan modification agreements with the banking institution under its line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, the Company’s chairman of the board of directors and a family member provided their individual guaranty for the remaining balance of the loans ($6.2 million). In consideration for executing his guaranty, the Company issued the chairman of the board of directors 28,571 shares of common stock with a grant date fair value of $80,000 (based upon the closing price of common stock on the date of issuance).

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 16: Subsequent Events The Company has evaluated subsequent events for disclosure purposes through November 9, 2015, and determined there are no other items to disclose except as set forth below: Note 7 and Note 15 are incorporated herein by reference. On October 30, 2015 the Company learned that an action was filed on October 27, 2015 in the District Court for the State of Nevada, Clark County, entitled Brian D. Gartner, derivatively on behalf of Musclepharm Corporation v. Brad Pyatt, Lawrence S. Meer, Donald W. Prosser, Richard Estalella, Jeremy R. Deluca, Michael J. Doron, Cory Gregory, L. Gary Davis, James J. Greenwell, John H. Bluher, and Daniel J. McClory and Musclepharm Corporation (Case No. A-15-726810-B). The complaint generally claims breaches of fiduciary duty against certain members of the board of directors and management of the Company. As of the date of this report, the Company has not been served in this matter. On November 6, 2015, the Company entered into a separation agreement with Cory Gregory, an executive vice president, for his amenable separation. Pursuant to the separation agreement, Cory Gregory will receive six months of base salary and the Company is entitled to use his image and website contributions in perpetuity.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. Acquisitions are included in the consolidated financial statements from the date of the acquisition. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements have been prepared in accordance with GAAP. In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of September 30, 2015, our results of operations for the three and nine months ended September 30, 2015 and 2014, and our cash flows for the nine months ended September 30, 2015 and 2014. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 16, 2015.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory, the assessment of useful lives and recoverability of long-lived assets, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which provides guidance on simplifying the presentation of debt issuance costs, requiring that debt issuance costs related to a recognized debt liability be presented in the consolidated balance sheets as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No, 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”), which further clarifies ASU 2015-03 as it relates to presentation and subsequent measurement of debt issuance costs related to line-of-credit arrangements. ASU 2015-15 allows an entity deferring and presenting debt issuance costs related to line-of-credit arrangements as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. Both ASU 2015-03 and ASU 2015-15 require retrospective adoption and will be effective for financial statement periods beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted. The Company has not early adopted ASU 2015-03 or ASU 2015-15 and the adoption of these standards is not expected to have a material effect on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15. In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation – Stock Compensation”, as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the consolidated financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material effect on the Company’s consolidated financial statements or disclosures. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition- Construction-Type and Production-Type Contracts.” ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2018 and, at that time, the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is permitted beginning January 1, 2017. The Company has not yet selected a transition method nor determined the effect of ASU 2014-09 on its ongoing financial reporting.

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
Balance Sheet Components (Tables)	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 1,603 $ 1,169 Work-in-process 151 101 Finished goods 17,566 19,799 Inventory $ 19,320 $ 21,069
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Furniture and fixtures $ 3,091 $ 4,041 Leasehold improvements 3,053 2,298 Manufacturing and lab equipment 1,577 1,388 Vehicles 1,081 470 Displays 485 488 Website 463 241 Office equipment and computers 520 — Construction in process 281 1,511 Property and equipment, gross 10,551 10,437 Less: accumulated depreciation and amortization (3,543 ) (2,632 ) Property and equipment, net $ 7,008 $ 7,805
Schedule of Intangible Assets	Intangible assets consist of the following (in thousands) and include the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel disclosed further in Note 11: September 30, 2015 Gross Value Accumulated Amortization Net Carrying Value Weighted- Average Useful Lives (Years) Amortized Intangible Assets Customer relationships $ 3,130 $ (365 ) $ 2,765 15.0 Non-compete agreements 69 (60 ) 9 2.0 Patents 2,211 (505 ) 1,706 7.9 Trademarks 880 (98 ) 782 6.7 Brand 4,020 (413 ) 3,607 10.5 Domain name 68 (33 ) 35 5.0 Total intangible assets $ 10,378 $ (1,474 ) $ 8,904 December 31, 2014 Gross Value Accumulated Amortization Net Carrying Value Weighted- Average Useful Lives (Years) Amortized Intangible Assets Customer relationships $ 3,130 $ (209 ) $ 2,921 15.0 Non-compete agreements 69 (35 ) 34 2.0 Patents 2,211 (293 ) 1,918 7.9 Trademarks 518 (20 ) 498 4.5 Brand 1,776 (118 ) 1,658 15.0 Domain name 68 (23 ) 45 5.0 Total intangible assets $ 7,772 $ (698 ) $ 7,074
Schedule of Estimated Future Amortization Expense of Intangible Assets	As of September 30, 2015, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2015 $ 280 2016 1,087 2017 1,067 2018 1,056 2019 1,052 2020 1,023 Thereafter 3,339 Total amortization expense $ 8,904

Other (Expense) Income, net (Ta

Other (Expense) Income, net (Tables)	9 Months Ended
Other (Expense) Income, net (Tables)	Sep. 30, 2015
Other Income and Expenses [Abstract]
Other (expense) Income, Net	During the three and nine months ended September 30, 2015 and 2014, other (expense) income, net consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Other (expense) income, net: Interest income $ — $ — $ — $ 223 Interest expense (99 ) (29 ) (357 ) (85 ) Change in fair value of derivative liabilities — — — 374 Gain on settlement of accounts payable — — — 31 Loss on marketable securities — — — (386 ) Bargain purchase gain and contingent asset gain on BioZone asset acquisition — 5,265 — 5,265 Foreign currency loss (456 ) (2 ) (717 ) (36 ) Other (4 ) — (16 ) 165 Total other (expense) income, net $ (559 ) $ 5,234 $ (1,090 ) $ 5,551

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2015
Debt Disclosure [Abstract]
Summary of Debt Obligations	The Company’s debt obligations consist of the following (in thousands): September 30, December 31, Line of credit $ 2,635 $ 8,000 Term loan 3,269 — Total debt obligations $ 5,904 $ 8,000

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
Restructuring (Tables)	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Schedule of Provision of Restructuring and Accrued Restructuring Charges	The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of September 30, 2015 (in thousands): Employee Contract Abandoned Total Balance as of December 31, 2014 $ — $ — $ — $ — Expensed 1,166 6,600 454 8,220 Cash payments (235 ) — (8 ) (243 ) Reclassification from accounts payable related to cancellation of certain contracts and sponsorship agreements — 2,120 — 2,120 Balance as of September 30, 2015 $ 931 $ 8,720 $ 446 $ 10,097
Schedule of Restructuring Charges	As a result of the reduction in force, 325,421 shares of restricted common stock vested in accordance with the original stock grant terms and condition and resulted in the recognition of employee stock based compensation of $1.7 million. During the three months ended September 30, 2015, in association with the restructuring, the Company recorded the following charges totaling $8.4 million (in thousands): Operating Expenses Employee Stock based compensation $ 1,692 Write-down of prepaid stock compensation related to terminated endorsement agreements, discontinued products and abandoned other arrangements including related prepaid assets 6,358 Write-off of long-lived assets related to the abandonment of certain lease facilities 380 Total other charges $ 8,430
Schedule of Future Payments Under The Restructuring Plan	The total future payments under the restructuring plan as of September 30, 2015 are as follows (in thousands): Remainder Year ending December 31, Outstanding Payments 2016 2017 2018 2019 2020 Total Contract termination costs $ 1,608 $ 7,112 $ — $ — $ — $ — $ 8,720 Employee severance costs 931 — — — — — 931 Abandoned leased facilities 47 134 98 77 79 11 446 Total future payments $ 2,586 $ 7,246 $ 98 $ 77 $ 79 $ 11 $ 10,097

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
Commitments and Contingencies (Tables)	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases	As of September 30, 2015, the Company’s future minimum lease payments are as follows (in thousands): Year Ending December 31, The remainder of 2015 $ 51 2016 198 2017 152 2018 117 2019 46 Total minimum lease payments 564 Less amounts representing interest (45 ) Present value of minimum lease payments $ 519
Contractual Obligation, Fiscal Year Maturity Schedule	The total future contractual payments as of September 30, 2015 are as follows (in thousands), although the Company is seeking to terminate or amend certain significant agreements for endorsement or sponsorship, which adjusted terms are not reflected in the below as of September 30, 2015: Remainder Year ending December 31, Future Contractual Payments 2016 2017 2018 2019 2020 Thereafter Total Endorsement $ 850 $ 2,560 $ 2,512 $ 2,500 $ 4,167 $ 5,000 $ 6,667 $ 24,256 Sponsorships 1,211 4,825 3,105 2,729 985 — — 12,855 Total future payments $ 2,061 $ 7,385 $ 5,617 $ 5,229 $ 5,152 $ 5,000 $ 6,667 $ 37,111

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity (Tables)	9 Months Ended
Stockholders' (Deficit) Equity (Tables)	Sep. 30, 2015
Equity [Abstract]
Schedule of Stockholders Equity	For the nine months ended September 30, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors, net of cancellations 186,354 $ 10,029 $ 3.48–8.60 Stock issued in conjunction with product line expansion 150,000 1,198 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 8.20 Stock issued in conjunction with attempted financing agreement 50,000 325 6.49 Stock issued in conjunction with consulting/endorsement agreement 55,189 320 5.30–5.85 Total 611,543 $ 13,266 $ 3.48–8.60 For the nine months ended September 30, 2014, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 66,878 $ 316 $ 3.48–8.70 BioZone acquisition (1) 1,200,000 8,833 8.20 Conversion of series D preferred stock to common stock 263,000 773 2.94 Deferred stock compensation on restricted stock awards issued for endorsement agreements 476,853 5,403 11.19–13.41 Total 2,006,731 $ 15,325 $ 2.94–13.41 (1) Subsequently reduced by 350,000 shares returned to treasury with a value of $4.6 million.
Treasury Stock Transactions Activity	For the nine months ended September 30, 2014, the Company’s treasury stock transactions are as follows: Transaction Type Number of Shares Weighted-Average Purchase of common stock in open market under the 2013 Stock Repurchase Plan 100,000 $ 13.63 Settlement of common stock held in escrow during BioZone acquisition (1) 350,000 13.20 Total 450,000 $ 13.30 (1) Returned to treasury.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Restricted Stock Units Activity	The activity of restricted stock awards granted to employees, executives, and board members was as follows: Number of Shares Weighted- Date Fair Value Unvested balance – December 31, 2014 2,631,987 $ 11.67 Granted 243,217 4.46 Vested (894,830 ) 10.37 Cancelled (100,000 ) 4.29 Unvested balance – September 30, 2015 1,880,374 $ 11.83

Net (Loss) Income per Share (Ta

Net (Loss) Income per Share (Tables)	9 Months Ended
Net (Loss) Income per Share (Tables)	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net (Loss) Income Per Share	The following table sets forth the computation of the Company’s basic and diluted net (loss) income per share for the periods presented (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net (loss) income $ (27,648 ) $ 603 $ (42,152 ) $ 2,404 Weighted-average common shares used in computing net (loss) income per share, basic 13,723,213 11,032,996 13,504,455 10,652,781 Effect of dilutive securities — 1,579,900 — 1,459,236 Weighted-average common shares used in computing net (loss) income per share, diluted 13,723,213 12,612,896 13,504,455 12,112,017 Net (loss) income per share, basic $ (2.01 ) $ 0.05 $ (3.12 ) $ 0.23 Net (loss) income per share, diluted $ (2.01 ) $ 0.05 $ (3.12 ) $ 0.20
Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following securities were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive: As of September 30, 2015 2014 Stock options (exercise price - $425/share) — 472 Warrants (exercise price - $4 - $1,275/share) — 100,089 Unvested restricted stock 1,880,374 1,495,117 Total common stock equivalents 1,880,374 1,595,678

Geographical Information (Table

Geographical Information (Tables)	9 Months Ended
Geographical Information (Tables)	Sep. 30, 2015
Segment Reporting [Abstract]
Revenue, Net by Geographic Area	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Revenue, net: United States $ 23,676 $ 28,677 $ 91,534 $ 88,718 International 10,306 19,091 34,246 56,000 Total revenue, net $ 33,982 $ 47,768 $ 125,780 $ 144,718

Description of Business and B35

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in cash used by operating activities	$ 7,709,000	$ (5,880,000)
Decrease in cash used by investing activities	(2,893,000)	(543,000)
Decrease in cash provided by financing activities	(2,274,000)	$ 3,979,000
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in cash used by operating activities	335,000
Decrease in cash used by investing activities	(2,900,000)
Decrease in cash provided by financing activities	$ (2,600,000)

Capstone Nutrition Agreements -

Capstone Nutrition Agreements - Additional Information (Detail) - USD ($)	Mar. 02, 2015	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Contractual obligation		$ 37,111,000
Common stock, par value		$ 0.001	$ 0.001
Amortization period of expense		6 years 5 months
I N I [Member]
Business Acquisition [Line Items]
Percentage ownership interest agreed to purchase	19.90%
Investment Warrants, Exercise Price	$ 0.01
Aggregate enterprise value	$ 200,000,000
I N I [Member] \| Common Class B [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 0.001
Capstone [Member]
Business Acquisition [Line Items]
Contractual obligation	$ 2,500,000
Contribution toward Capstone Facility Build		$ 2,500,000
Long-Term Investments [Member]
Business Acquisition [Line Items]
Recorded value of Asset		977,000
Prepaid Expenses and Other Current Assets [Member]
Business Acquisition [Line Items]
Prepaid expenses and other assets		$ 1,500,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Raw materials	$ 1,603	$ 1,169
Work-in-process	151	101
Finished goods	17,566	19,799
Inventory	$ 19,320	$ 21,069

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Balance Sheet Components [Line Items]
Inventory write down related to corporate restructuring	$ 1,300,000	$ 1,262,000		$ 1,262,000
Depreciation and amortization expense		492,000	$ 303,000	1,300,000	$ 950,000
Write-off of long-lived assets related to the abandonment of certain lease facilities		380,000		380,000
Amortization of intangible assets		$ 278,000		$ 776,000	$ 422,000
Restatement Adjustment [Member]
Balance Sheet Components [Line Items]
Amortization of intangible assets			$ 156,000

Balance Sheet Components - Sc39

Balance Sheet Components - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,551	$ 10,437
Less: accumulated depreciation and amortization	(3,543)	(2,632)
Property and equipment, net	7,008	7,805
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,091	4,041
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,053	2,298
Manufacturing and Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,577	1,388
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,081	470
Displays [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	485	488
Website [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	463	241
Office Equipment and Computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	520
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 281	$ 1,511

Balance Sheet Components - Sc40

Balance Sheet Components - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 10,378	$ 7,772
Finite-Lived Intangible Assets, Accumulated Amortization	(1,474)	(698)
Finite-Lived Intangible Assets, Net, Total	8,904	7,074
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,130	3,130
Finite-Lived Intangible Assets, Accumulated Amortization	(365)	(209)
Finite-Lived Intangible Assets, Net, Total	$ 2,765	$ 2,921
Finite-Lived Intangible Asset, Useful Life	15 years	15 years
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 69	$ 69
Finite-Lived Intangible Assets, Accumulated Amortization	(60)	(35)
Finite-Lived Intangible Assets, Net, Total	$ 9	$ 34
Finite-Lived Intangible Asset, Useful Life	2 years	2 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,211	$ 2,211
Finite-Lived Intangible Assets, Accumulated Amortization	(505)	(293)
Finite-Lived Intangible Assets, Net, Total	$ 1,706	$ 1,918
Finite-Lived Intangible Asset, Useful Life	7 years 10 months 24 days	7 years 10 months 24 days
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 880	$ 518
Finite-Lived Intangible Assets, Accumulated Amortization	(98)	(20)
Finite-Lived Intangible Assets, Net, Total	$ 782	$ 498
Finite-Lived Intangible Asset, Useful Life	6 years 8 months 12 days	4 years 6 months
Brand [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 4,020	$ 1,776
Finite-Lived Intangible Assets, Accumulated Amortization	(413)	(118)
Finite-Lived Intangible Assets, Net, Total	$ 3,607	$ 1,658
Finite-Lived Intangible Asset, Useful Life	10 years 6 months	15 years
Domain Name [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 68	$ 68
Finite-Lived Intangible Assets, Accumulated Amortization	(33)	(23)
Finite-Lived Intangible Assets, Net, Total	$ 35	$ 45
Finite-Lived Intangible Asset, Useful Life	5 years	5 years

Balance Sheet Components - Sc41

Balance Sheet Components - Schedule of Estimated Future Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
The remainder of 2015	$ 280
2,016	1,087
2,017	1,067
2,018	1,056
2,019	1,052
2,020	1,023
Thereafter	3,339
Finite-Lived Intangible Assets, Net, Total	$ 8,904	$ 7,074

Other (Expense) Income, net - O

Other (Expense) Income, net - Other (Expense) Income, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other (expense) income, net:
Interest income				$ 223
Interest expense	$ (99)	$ (29)	$ (357)	(85)
Change in fair value of derivative liabilities				374
Gain on settlement of accounts payable				31
Loss on marketable securities				(386)
Bargain purchase gain and contingent asset gain on BioZone asset acquisition		5,265		5,265
Foreign currency loss	(456)	(2)	(717)	(36)
Other	(4)		(16)	165
Total other (expense) income, net	$ (559)	$ 5,234	$ (1,090)	$ 5,551

Debt - Summary of Debt Obligati

Debt - Summary of Debt Obligations (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Line of credit	$ 2,635	$ 8,000
Term loan	3,269
Total debt obligations	$ 5,904	$ 8,000

Debt - Additional Information (

Debt - Additional Information (Detail)	Oct. 09, 2015USD ($)shares	Feb. 28, 2015USD ($)Installmentsshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)shares	Sep. 30, 2014USD ($)shares	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 8,000,000		$ 8,000,000
Line of Credit Facility, Expiration Date			Sep. 30, 2017
Debt Instrument, Basis Spread on Variable Rate			2.00%
Line of Credit Facility, Interest Rate Description				Prime rate plus 2%
Line of credit facility, interest rate			5.25%
Line of credit				$ 2,635,000		$ 8,000,000
Principal amount of promissory note		$ 4,000,000
Interest rate		5.25%
Number of installments \| Installments		36
Debt Instrument Maturity Date		Feb. 28, 2018
Prepayment penalties		1.00%
Debt Issuance Costs		$ 40,000
Term loan outstanding borrowings				$ 3,269,000
Treasury share used to secure promissory note \| shares		860,900		860,900
Stock issued to chairman of the board of directors, shares \| shares				186,354	66,878
Stock issued to chairman of the board of directors, value				$ 10,029,000	$ 316,000
Subsequent Event [Member] \| Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument Maturity Date	Jan. 15, 2016
Loan amount outstanding	$ 6,200,000
Subsequent Event [Member] \| Board of Directors [Member] \| Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Stock issued to chairman of the board of directors, shares \| shares	28,571
Stock issued to chairman of the board of directors, value	$ 80,000

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		$ 17,900
Restructuring charges to be paid in cash	$ 8,220,000	8,220
Employee stock based compensation	1,692	1,700
Total other charges	8,430	$ 8,430
Restricted Stock [Member]
Restructuring Cost and Reserve [Line Items]
Number of restricted stock vested		(894,830)
Cost of Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		$ 1,300
Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		16,600
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	6,600	6,600
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	1,200	1,166
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	$ 454	$ 454

Restructuring - Schedule of Pro

Restructuring - Schedule of Provision of Restructuring and Accrued Restructuring Charges (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Expensed	$ 8,220,000	$ 8,220
Cash payments		(243)
Reclassification from accounts payable related to cancellation of certain contracts and sponsorship agreements		2,120
Balance as of September 30, 2015	10,097	10,097
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Expensed	1,200	1,166
Cash payments		(235)
Balance as of September 30, 2015	931	931
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Expensed	6,600	6,600
Reclassification from accounts payable related to cancellation of certain contracts and sponsorship agreements		2,120
Balance as of September 30, 2015	8,720	8,720
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Expensed	454	454
Cash payments		(8)
Balance as of September 30, 2015	$ 446	$ 446

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Charges (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Employee stock based compensation	$ 1,692,000	$ 1,700,000
Write-down of prepaid stock compensation related to terminated endorsement agreements, discontinued products and abandoned other arrangements including related prepaid assets	6,358,000
Write-off of long-lived assets related to the abandonment of certain lease facilities	380,000	380,000
Total other charges	$ 8,430,000	$ 8,430,000

Restructuring - Schedule of Fut

Restructuring - Schedule of Future Payments Under The Restructuring Plan (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Remainder of 2015	$ 2,586
2,016	7,246
2,017	98
2,018	77
2,019	79
2,020	11
Total	10,097
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2015	1,608
2,016	7,112
Total	8,720
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2015	931
Total	931
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2015	47
2,016	134
2,017	98
2,018	77
2,019	79
2,020	11
Total	$ 446

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Vehicle	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)Vehicle
Commitment And Contingencies [Line Items]
Operating Lease Expire Term				2,029
Operating Leases, Rent Expense, Net		$ 422,000	$ 356,000	$ 1,200,000	$ 989,000
Line of Credit Facility, Maximum Borrowing Capacity			$ 8,000,000		$ 8,000,000
Capital Lease Expire Term				May 2,019
Capital Lease Obligations	$ 519,000	$ 519,000		$ 519,000		$ 265,000
Product Liability Insurance Deduction				10,000
Aggregate Product Liability Retained Loss				$ 20,000,000
Lease expiration term				2,022
Securities And Exchange Commission [Member]
Commitment And Contingencies [Line Items]
Final settlement with the SEC	700,000
Penalty amount paid into escrow	$ 400,000
Fleet Lease Program [Member]
Commitment And Contingencies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 1,800,000
Number of vehicles acquired under capital lease \| Vehicle				19
Fleet Lease Program [Member] \| Maximum [Member]
Commitment And Contingencies [Line Items]
Number of vehicles for lease \| Vehicle						50

Commitments and Contingencies50

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Capital Leases (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
The remainder of 2015	$ 51
2,016	198
2,017	152
2,018	117
2,019	46
Total minimum lease payments	564
Less amounts representing interest	(45)
Present value of minimum lease payments	$ 519

Commitments and Contingencies51

Commitments and Contingencies - Contractual Obligation, Fiscal Year Maturity Schedule (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	$ 2,061
2,016	7,385
2,017	5,617
2,018	5,229
2,019	5,152
2,020	5,000
Thereafter	6,667
Future Contractual Obligation, Total	37,111
Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	850
2,016	2,560
2,017	2,512
2,018	2,500
2,019	4,167
2,020	5,000
Thereafter	6,667
Future Contractual Obligation, Total	24,256
Sponsorship [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2015	1,211
2,016	4,825
2,017	3,105
2,018	2,729
2,019	985
Future Contractual Obligation, Total	$ 12,855

Stockholders' (Deficit) Equit52

Stockholders' (Deficit) Equity - Schedule of Stockholders Equity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Stock issued to employees, executives and directors, net of cancellations, Valuation	$ 10,029	$ 316
Conversion of series D preferred stock to common stock, Valuation		$ 773
Conversion of series D preferred stock to common stock, Quantity		263,000
Stock issued in conjunction with product line expansion, Valuation	1,198
Deferred stock compensation on restricted stock awards issued for endorsement agreements, Valuation		$ 5,403
Deferred stock compensation on restricted stock awards issued for endorsement agreements, Quantity		476,853
Stock issued in conjunction with acquisition, Valuation	1,394
Stock issued in conjunction with attempted financing agreement, Valuation	325
Stock issued in conjunction with consulting/endorsement agreement, Valuation	320
Total, Valuation	$ 13,266	$ 15,325
Conversion of series D preferred stock to common stock, Range of Value per Share		$ 2.94
Stock issued in conjunction with product line expansion, Range of Value per Share	$ 7.99
Stock issued in conjunction with attempted financing agreement, Range of Value per Share	$ 6.49
Stock issued to employees, executives and directors, net of cancellations, Quantity	186,354	66,878
Stock issued in conjunction with product line expansion, Quantity	150,000
Stock issued in conjunction with attempted financing agreement, Quantity	50,000
Stock issued in conjunction with consulting/endorsement agreement, Quantity	55,189
Total, Quantity	611,543	2,006,731
Minimum [Member]
Class of Stock [Line Items]
Deferred stock compensation on restricted stock awards issued for endorsement agreements, Range of Value per Share		$ 11.19
Stock issued to employees, executives and directors, net of cancellations, Range of Value per Share	$ 3.48	3.48
Stock issued in conjunction with consulting/endorsement agreement, Range of Value per Share	5.30
Total, Range of Value per Share	3.48	2.94
Maximum [Member]
Class of Stock [Line Items]
Deferred stock compensation on restricted stock awards issued for endorsement agreements, Range of Value per Share		13.41
Stock issued to employees, executives and directors, net of cancellations, Range of Value per Share	8.60	8.70
Stock issued in conjunction with consulting/endorsement agreement, Range of Value per Share	5.85
Total, Range of Value per Share	$ 8.60	$ 13.41
Biozone Asset Acquisition [Member]
Class of Stock [Line Items]
Stock issued in conjunction with acquisition, Valuation		$ 8,833
Stock issued in conjunction with acquisition, Range of Value per Share		$ 8.20
Stock issued in conjunction with acquisition, Quantity		1,200,000
Muscle Pharm Apparel [Member]
Class of Stock [Line Items]
Stock issued in conjunction with acquisition, Valuation	$ 1,394
Stock issued in conjunction with acquisition, Range of Value per Share	$ 8.20
Stock issued in conjunction with acquisition, Quantity	170,000

Stockholders' (Deficit) Equit53

Stockholders' (Deficit) Equity - Schedule of Stockholders Equity (Parenthetical) (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Number of Treasury Shares, Acquired	0	450,000
Settlement of Common Stock Held in Escrow [Member] \| Biozone Asset Acquisition [Member]
Class of Stock [Line Items]
Number of Treasury Shares, Acquired		350,000
Treasury stock, value, acquired, cost method		$ 4.6

Stockholders' (Deficit) Equit54

Stockholders' (Deficit) Equity - Additional Information (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Feb. 28, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Number of Treasury Shares, Acquired	0	450,000
Treasury Stock, shares	875,621			875,621
Treasury share used to secure promissory note	860,900		860,900

Stockholders' (Deficit) Equit55

Stockholders' (Deficit) Equity - Treasury Stock Transactions Activity (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity, Class of Treasury Stock [Line Items]
Number of Treasury Shares, Acquired	0	450,000
Weighted-Average Purchase Price of Treasury Shares Acquired		$ 13.30
2013 Stock Repurchase Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Number of Treasury Shares, Acquired		100,000
Weighted-Average Purchase Price of Treasury Shares Acquired		$ 13.63
Settlement of Common Stock Held in Escrow [Member] \| Biozone Asset Acquisition [Member]
Equity, Class of Treasury Stock [Line Items]
Number of Treasury Shares, Acquired		350,000
Weighted-Average Purchase Price of Treasury Shares Acquired		$ 13.20

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Detail) - Restricted Stock [Member] - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested Beginning Balance		2,631,987
Number of Shares, Granted	0	243,217
Number of Shares, Vested		(894,830)
Number of Shares, Cancelled		(100,000)
Number of Shares, Unvested Ending Balance		1,880,374
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance		$ 11.67
Weighted-Average Grant Date Fair Value, Granted		4.46
Weighted-Average Grant Date Fair Value, Vested		10.37
Weighted-Average Grant Date Fair Value, Cancelled		4.29
Weighted-Average Grant Date Fair Value, Unvested Ending Balance		$ 11.83

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2015	Jul. 31, 2015	May. 31, 2015	Jan. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards issued related to financing agreement							150,000
Prepaid stock compensation write down					$ 6,358,000
Total consideration related to the acquisition of the Apparel in cash							$ 850,000
Energy Drink Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards issued related to financing agreement				150,000
Restricted stock awards grant date fair value				$ 1,200,000
Prepaid stock compensation amortization period				10 years
Prepaid stock compensation write down	$ 1,100,000
Worldwide Apparel, LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total consideration related to the acquisition of the Apparel in cash							$ 850,000
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued							170,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable							$ 1,400,000
Finite-Lived Intangible Asset, Useful Life							7 years
Total cost of Apparel acquisition							$ 2,200,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted					184,000		1,100,000	$ 1,500,000
Total unrecognized expense for unvested restricted stock awards					$ 11,300,000		$ 11,300,000		$ 20,700,000
Total unrecognized expense for unvested restricted stock awards, weighted average period (in years)							3 years		2 years 7 months 6 days
Restricted stock granted to employees and board members						0	243,217
Restricted Stock [Member] \| Energy Drink Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards vesting period				3 years
Restricted Stock Awards Issued Related to Financing Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards issued related to financing agreement			50,000
Restricted stock awards grant date fair value			$ 325,000
Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards issued related to financing agreement			50,000
Restricted stock awards grant date fair value		$ 28,000
Prepaid stock compensation write down	$ 268,000
Share issued within ten days after each subsequent three month period term			$ 25,000
Weighted average stock issuance prior period		15 days
Number of restricted stock awards issued related to consulting and endorsement agreement		5,189
Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member] \| Additional Paid-In Capital [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards grant date fair value			$ 292,000

Net (Loss) Income per Share - S

Net (Loss) Income per Share - Schedule of Basic and Diluted Net (Loss) Income Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net (loss) income	$ (27,648)	$ 603	$ (42,152)	$ 2,404
Weighted-average common shares used in computing net (loss) income per share, basic	13,723,213	11,032,996	13,504,455	10,652,781
Effect of dilutive securities		1,579,900		1,459,236
Weighted-average common shares used in computing net (loss) income per share, diluted	13,723,213	12,612,896	13,504,455	12,112,017
Net (loss) income per share, basic	$ (2.01)	$ 0.05	$ (3.12)	$ 0.23
Net (loss) income per share, diluted	$ (2.01)	$ 0.05	$ (3.12)	$ 0.20

Net (Loss) Income per Share - A

Net (Loss) Income per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,880,374	1,595,678
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		472
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		100,089
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,880,374	1,495,117

Net (Loss) Income per Share -60

Net (Loss) Income per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Parenthetical) (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 425	$ 425
Warrant [Member] \| Minimum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	4	4
Warrant [Member] \| Maximum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 1,275	$ 1,275

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 71	$ 94	$ 104	$ 171

Geographic Information - Revenu

Geographic Information - Revenue, Net by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue, net:
Revenue, net	$ 33,982	$ 47,768	$ 125,780	$ 144,718
United States [Member]
Revenue, net:
Revenue, net	23,676	28,677	91,534	88,718
International [Member]
Revenue, net:
Revenue, net	$ 10,306	$ 19,091	$ 34,246	$ 56,000

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($)	Oct. 09, 2015	Feb. 28, 2015	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Stock issued to chairman of the board of directors, shares			186,354	66,878
Stock issued to chairman of the board of directors, value			$ 10,029,000	$ 316,000
Debt Instrument Maturity Date		Feb. 28, 2018
Subsequent Event [Member] \| Loan Modification Agreement [Member]
Related Party Transaction [Line Items]
Loan amount outstanding	$ 6,200,000
Debt Instrument Maturity Date	Jan. 15, 2016
Subsequent Event [Member] \| Board of Directors [Member] \| Loan Modification Agreement [Member]
Related Party Transaction [Line Items]
Stock issued to chairman of the board of directors, shares	28,571
Stock issued to chairman of the board of directors, value	$ 80,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	9 Months Ended
Subsequent Events - Additional Information (Detail)	Sep. 30, 2015
Cory Gregory [Member]
Subsequent Event [Line Items]
Separation agreement description	Pursuant to the separation agreement, Cory Gregory will receive six months of base salary and the Company is entitled to use his image and website contributions in perpetuity.